Merck KGaA buys into Abbisko’s late-stage joint tumor med for $70M upfront

Merck KGaA’s year-long quest to become leaner and rely more on external innovation has led to a $70 million partnership with Chinese biotech Abbisko Therapeutics for rights to a late-stage joint tumor med called pimicotinib.